Abstract |
Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation.
|
Authors | J Anthony Brandon, C Darrell Jennings, Alan M Kaplan, J Scott Bryson |
Journal | Cytokine
(Cytokine)
Vol. 61
Issue 3
Pg. 732-5
(Mar 2013)
ISSN: 1096-0023 [Electronic] England |
PMID | 23402791
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Cytokines
- Inflammation Mediators
- Interleukin-23 Subunit p19
|
Topics |
- Adoptive Transfer
- Animals
- Cytokines
(biosynthesis)
- Female
- Graft vs Host Disease
(immunology, therapy)
- Inflammation Mediators
(metabolism)
- Interleukin-23 Subunit p19
(antagonists & inhibitors, metabolism)
- Mice
- Transplantation, Isogeneic
|